Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alzheimer’s Disease Market Report Overview

Alzheimer’s Disease and MCI market size across the 8MM was valued at $2.2 billion in 2020 and is expected to achieve a CAGR of more than 19% during 2020-2030. AD is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. Mild cognitive impairment (MCI) is a phase of the AD continuum in which a gradually progressive cognitive decline occurs and may even become clinically relevant.

Alzheimer’s Disease Market Outlook, 2020-2030 ($ Billion)

Alzheimer’s Disease Market Outlook, 2020-2030 ($ Billion)

To gain more information about the Alzheimer’s Disease market forecast, download a free report sample

The Alzheimer’s Disease market research report provides an analysis of the current and future market competition in the global AD therapeutics market. The report also offers an insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Market Size (2020) $2.2 billion
CAGR (2020 – 2030) >19%
Key Countries ·       The US

·       China

·       France

·       Germany

·       Italy

·       The UK

·       Spain

·       Japan

Leading Players ·       Eisai’s Aricept (donepezil)

·       Novartis’ Exelon (rivastigmine)

·       Johnson & Johnson’s Razadyne (galantamine)

·       AbbVie/Lundbeck Namenda (memantine)

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Alzheimer’s Disease Market Drivers

The main drivers of the AD market over the forecast period are the entry of disease-modifying therapies (DMTs), including the passive immunotherapies Aduhelm (aducanumab), Leqembi (lecanemab), and donanema. Factors such as the launch of novel symptomatic therapies such as brexpiprazole and the rising prevalence of AD and MCI will also propel the market growth in the coming years.

Alzheimer’s Disease Market Segmentation by Countries

Some of the key countries in the Alzheimer’s Disease market in the 8MM are the US, France, Germany, Italy, the UK, China, Spain, and Japan. The US had the highest share of the market in 2020.

Alzheimer’s Disease Market Analysis by Countries, 2020 (%)

Alzheimer’s Disease Market Analysis by Countries, 2020 (%)

For more countries’ insights into the Alzheimer’s Disease market, download a free report sample

Alzheimer’s Disease Market - Competitive Landscape

The current AD market consists of four main brands—Eisai’s Aricept (donepezil), Novartis’ Exelon (rivastigmine), Johnson & Johnson’s Razadyne (galantamine), and AbbVie/Lundbeck Namenda (memantine). All of them can confer modest symptomatic benefits. However, given that these brands have all reached or are nearing the expiration of their patents, large and small players in the industry are active in the pursuit of more effective medications to satisfy the abundant unmet needs that exist in this market.

Scope

  • Overview of Alzheimer’s disease (AD), including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized AD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (mild cognitive impairment, mild AD, moderate AD, and severe AD) forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AD therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD treatment. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

  • Report deliverables include a Word report and an Excel-based forecast model
  • Forecasts include the 8MM
  • Forecasts cover from 2020-2030
  • The prevalence of AD is increasing in line with an aging global population in the 8MM.
  • The current competitive landscape in AD mostly consists of symptomatic treatments, of which acetylcholinesterases are the most commonly prescribed drug class for managing AD.
  • The greatest unmet need in the AD market is curative treatments, followed by the wider availability of disease-modifying therapies.
  • The AD pipeline is diverse with a wide variety of unique mechanisms of action present, highlighting the poorly understood nature of the disease and the many mechanisms thought to be involved in disease pathology.
  • The AD market will exhibit significant growth between 2020 and 2030, driven by the launch of 23 pipeline agents, including several drug candidates that have the potential to modify the underlying cause of the disease.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Alzheimer’s Disease therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alzheimer’s Disease therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships

AbbVie
AB Science
AgeneBio
AlphaCognition
Alzheon
Anavex Life Sciences
AriBio
Athira Pharma
Axsome Therapeutics
Biogen
BioVie
BioXcel Therapeutics
Cassava Sciences
Cerecin
Changchun Huayang High-Tech
Corium
Daiichi Sankyo
Eisai
Eli Lilly
Grifols
Johnson & Johnson
Lundbeck
Luye Pharma
Mertz Pharma
Novartis
Novo Nordisk
Ono Pharmaceutical
Otsuka Pharmaceutical
Shanghai Green Valley Pharmaceutical
Suven Life Sciences
Takeda
TauRx Therapeutics
Teikoku Seiyaku
Towa Pharmaceutical

Table of Contents

1 Alzheimer’s Disease: Executive Summary – Updated Apr 2023, based on events up to Apr 13, 2023

1.1 Alzheimer’s market forecast to see double-digit sales growth out to 2030

1.2 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2030

1.3 Opportunities to fulfil key unmet needs will remain

1.4 Novel late-stage pipeline drugs will be a key driver of growth

1.5 What do physicians think?

2 Introduction – Updated Apr 2023

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview – Updated Apr 2023, based on events up to Apr 13, 2023

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Disease staging systems

3.3 Symptoms

3.4 Prognosis

3.5 Quality of life

4 Epidemiology – Updated Apr 2023

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.5 Epidemiological Forecast for AD (2020–30)

4.5.1 Total prevalent cases of AD

4.5.2 Age-specific total prevalent cases of AD

4.5.3 Sex-specific total prevalent cases of AD

4.5.4 Total prevalent cases of AD by severiy

4.5.5 Diagnosed prevalent cases of AD

4.5.6 Age-specific diagnosed prevalent cases of AD

4.5.7 Sex-specific diagnosed prevalent cases of AD

4.5.8 Diagnosed prevalent cases of AD by severity

4.5.9 Total prevalent cases of MCI

4.5.10 Age-specific total prevalent cases of MCI

4.5.11 Sex-specific total prevalent cases of MCI

4.5.12 Diagnosed prevalent cases of MCI

4.5.13 Age-specific diagnosed prevalent cases of MCI

4.5.14 Sex-specific diagnosed prevalent cases of MCI

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management – Updated Apr 2023, based on events up to Apr 13, 2023

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Competitive Assessment – Updated Apr 2023, based on events up to Apr 13, 2023

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated Apr 2023, based on events up to Apr 13, 2023

7.1 Overview

7.2 Wider availability of DMTs

7.3 Diagnosis in the prodromal or presymptomatic stages

7.4 Improved control of symptoms

7.5 Easier access to treatment

8 R&D Strategies – Updated Apr 2023, based on events up to Apr 13, 2023

8.1 Overview

8.1.1 Targeting Aβ

8.1.2 Novel MOAs

8.1.3 Combination therapies

8.2 Clinical trials design

8.2.1 Endpoints

8.2.2 Inclusion/exclusion criteria

9 Pipeline Assessment – Updated Apr 2023, based on events up to Apr 13, 2023

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis – Updated Apr 2023, based on events up to Apr 13, 2023

10.1 Overview

10.2 Competitive assessment

10.2.1 Injectable DMTs

10.2.2 Oral DMTs

10.2.3 Therapies for agitation associated with AD

10.2.3 Other symptomatic therapies

11 Current and Future Players – Updated Apr 2023, based on events up to Apr 13, 2023

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated Apr 2023, based on events up to Apr 13, 2023

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 China

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix – Updated Apr 2023, based on events up to Apr 13, 2023

13.1 Bibliography

13.2 Abbreviations

13.3 AD clinical development pipeline

13.4 Methodology

13.4.1 Forecasting methodology

13.5 Primary research – KOLs and payers interviewed for this report

13.5.1 KOLs

13.5.2 Payers

13.6 Primary research – prescriber survey

13.7 About the authors

13.7.1 Analyst

13.7.2 Therapy Area Director

13.7.3 Epidemiologist

13.7.4 Managing Epidemiologist

13.7.5 Vice President of Disease Analysis and Intelligence

13.7.6 Global Head and EVP of Healthcare Operations and Strategy

Contact Us

Table

Table 1: MCI and AD: Key metrics in the 8MM

Table 2: Three-stage classification of AD

Table 3: The seven-stage Reisburg Scale of AD

Table 4: Proposed NIA-AA staging classification for preclinical AD

Table 5: Common symptoms of AD

Table 6: Risk factors and comorbidities for AD

Table 7: Summary of NINCDS-ARDA diagnostic criteria for AD

Table 8: Most prescribed drugs for AD by class in the 8MM

Table 9: Most prescribed off-label drug classes for secondary AD symptoms by class in the 8MM

Table 10: Treatment Guidelines for AD

Table 11: AD market – global drivers and barriers, 2020–30

Table 12: Key events impacting sales for AD in the US, 2020–30

Table 13: AD market – drivers and barriers in the US, 2020–30

Table 14: Key events impacting sales for AD in the 5EU, 2020–30

Table 15: AD market – drivers and barriers in the 5EU, 2020–30

Table 16: Key events impacting sales for AD in Japan, 2020–30

Table 17: AD market – drivers and barriers in Japan, 2020–30

Table 18: Key events impacting sales for AD in China, 2020–30

Table 19: AD market – drivers and barriers in China, 2020–30

Table 20: AD clinical development pipeline by drug class

Table 21: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for AD in 2020 and 2030

Figure 2: Analysis of the company portfolio gap in AD during the forecast period

Figure 3: Competitive assessment of the injectable DMTs benchmarked against Aduhelm

Figure 4: AD biomarker tests by [athophysiology

Figure 5: 8MM, total prevalence of AD (%), men and women, ages ≥60 years, 2020

Figure 6: 8MM, total prevalence of MCI (%), men and women, ages ≥60 years, 2020

Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD based on the DSM-IV and clinical criteria

Figure 8: 8MM, sources used and not used to forecast the total prevalent cases of MCI

Figure 9: 8MM, sources used to forecast the total prevalent cases of AD by severity

Figure 10: 8MM, total prevalent cases of AD, both sexes, ages ≥60 years, 2020

Figure 11: 8MM total prevalent cases of AD, by sex, ages ≥60 years, N, 2020

Figure 12: 8MM, total prevalent cases of AD, by age, both sexes, N, 2020

Figure 13: 8MM, total prevalent cases of AD, by severity, both sexes, ages ≥60 years, N, 2020

Figure 14: 8MM, diagnosed prevalent cases of AD, both sexes, ages ≥60 years, N, 2020

Figure 15: 8MM, diagnosed prevalent cases of AD, by sex, ages ≥60 years, N, 2020

Figure 16: 8MM, diagnosed prevalent cases of AD by age, both sexes, N, 2020

Figure 17: 8MM, diagnosed prevalent cases of AD by severity, both sexes, ages ≥60 years, N, 2020

Figure 18: 8MM, total prevalent cases of MCI, both sexes, ages ≥60 years

Figure 19: 8MM, total prevalent cases of MCI, by sex, ages ≥60 years, N, 2020

Figure 20: 8MM, total prevalent cases of MCI, by age, both sexes, N, 2020

Figure 21: 8MM, diagnosed prevalent cases of MCI, both sexes, ages ≥60 years

Figure 22: 8MM, diagnosed prevalent cases in MCI, by sex, ages ≥60 years, N, 2020

Figure 23: 8MM, diagnosed prevalent cases in MCI, by age, both sexes, N, 2020

Figure 24: 8MM, treatment algorithm for AD

Figure 25: 8MM, disease management timeline for AD

Figure 26: Unmet needs and opportunities in AD

Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AD in the 8MM during the forecast period

Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for agitation associated with AD in the 8MM during the forecast period

Figure 29: Competitive assessment of the injectable pipeline DMTs benchmarked against Aduhelm (aducanumab)

Figure 30: Competitive assessment of the oral pipeline DMTs benchmarked against oral generic donepezil

Figure 31: Competitive assessment of the pipeline agents for agitation associated with AD benchmarked against Risperdal (risperidone)

Figure 32: Competitive assessment of the other symptomatic therapies benchmarked against donepezil (oral)

Figure 33: Analysis of the company portfolio gap in AD during the forecast period

Figure 34: Global (8MM) sales forecast by country for AD in 2020 and 2030

Figure 35: Global (8MM) sales forecast by class for AD in 2020 and 2030

Figure 36: Sales forecast by class for AD in the US in 2020 and 2030

Figure 37: Sales forecast by class for AD in the 5EU in 2020 and 2030

Figure 38: Sales forecast by class for AD in Japan in 2020 and 2030

Figure 39: Sales forecast by class for AD in China in 2020 and 2030

Frequently asked questions

Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 in real time.

  • Access a live Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.